1. Home
  2. RUN vs ARQT Comparison

RUN vs ARQT Comparison

Compare RUN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sunrun Inc.

RUN

Sunrun Inc.

HOLD

Current Price

$12.27

Market Cap

3.1B

Sector

Miscellaneous

ML Signal

HOLD

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$22.70

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RUN
ARQT
Founded
2007
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.3B
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
RUN
ARQT
Price
$12.27
$22.70
Analyst Decision
Buy
Strong Buy
Analyst Count
20
6
Target Price
$18.80
$34.00
AVG Volume (30 Days)
7.8M
909.3K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
113.35
88.79
EPS
1.71
N/A
Revenue
$858,578,000.00
$376,072,000.00
Revenue This Year
$2.81
$34.85
Revenue Next Year
$4.54
$29.39
P/E Ratio
$6.91
N/A
Revenue Growth
12.97
91.34
52 Week Low
$5.38
$12.42
52 Week High
$22.44
$31.77

Technical Indicators

Market Signals
Indicator
RUN
ARQT
Relative Strength Index (RSI) 44.19 45.68
Support Level $11.90 $22.56
Resistance Level $13.57 $23.46
Average True Range (ATR) 0.66 0.89
MACD 0.05 -0.12
Stochastic Oscillator 35.67 26.35

Price Performance

Historical Comparison
RUN
ARQT

About RUN Sunrun Inc.

Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Share on Social Networks: